<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title>PLoS Neglected Tropical Diseases</journal-title><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PNTD-RA-0331R2</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0000304</article-id><article-id pub-id-type="pmid">18827882</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Complex Traits</subject><subject>Immunology/Genetics of the Immune System</subject><subject>Immunology/Immunity to Infections</subject><subject>Infectious Diseases/Tropical and Travel-Associated Diseases</subject><subject>Infectious Diseases/Viral Infections</subject><subject>Virology/Mechanisms of Resistance and Susceptibility, including Host Genetics</subject></subj-group></article-categories><title-group><article-title>Protective and Enhancing HLA Alleles, HLA-DRB1&#x0002a;0901 and HLA-A&#x0002a;24, for Severe Forms of Dengue Virus Infection, Dengue Hemorrhagic Fever and Dengue Shock Syndrome</article-title><alt-title alt-title-type="running-head">HLA-DRB1&#x0002a;0901 and A&#x0002a;24 Affect DHF/DSS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lan</surname><given-names>Nguyen Thi Phuong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kikuchi</surname><given-names>Mihoko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huong</surname><given-names>Vu Thi Que</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ha</surname><given-names>Do Quang</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thuy</surname><given-names>Tran Thi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tham</surname><given-names>Vo Dinh</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tuan</surname><given-names>Ha Manh</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tuong</surname><given-names>Vo Van</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nga</surname><given-names>Cao Thi Phi</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Dat</surname><given-names>Tran</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oyama</surname><given-names>Toshifumi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Morita</surname><given-names>Kouichi</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yasunami</surname><given-names>Michio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hirayama</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Center of International Collaborative Research, Nagasaki University, Japan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Laboratory of Arbovirus, Pasteur Institute in Ho Chi Minh City, Vietnam</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Children's Hospital No.2, Ho Chi Minh City, Vietnam</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Center for Preventive Medicine, Vinh Long Province, Vietnam</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Global COE program, Nagasaki University, Japan</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Harris</surname><given-names>Eva</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California Berkeley, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>hiraken@nagasaki-u.ac.jp</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: NTPL MK VTQH DQH TTT VDT HMT TVD KM MY KH. Performed the experiments: NTPL MK VTQH MY KH. Analyzed the data: NTPL MK VTQH MY KH. Contributed reagents/materials/analysis tools: NTPL MK VTQH DQH TTT VDT HMT VVT CTPN TVD TO KM MY KH. Wrote the paper: NTPL MK VTQH KM MY KH.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>1</day><month>10</month><year>2008</year></pub-date><volume>2</volume><issue>10</issue><elocation-id>e304</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2007</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2008</year></date></history><copyright-statement>Lan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Dengue virus (DV) infection is one of the most important mosquito-borne diseases in the tropics. Recently, the severe forms, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), have become the leading cause of death among children in Southern Vietnam. Protective and/or pathogenic T cell immunity is supposed to be important in the pathogenesis of DHF and DSS.</p></sec><sec><title>Methodology/Principal Findings</title><p>To identify HLA alleles controlling T cell immunity against dengue virus (DV), we performed a hospital-based case control study at Children's Hospital No.2, Ho Chi Minh City (HCMC), and Vinh Long Province Hospital (VL) in Southern Vietnam from 2002 to 2005. A total of 211 and 418 patients with DHF and DSS, respectively, diagnosed according to the World Health Organization (WHO) criteria, were analyzed for their characteristic HLA-A, -B and -DRB1 alleles. Four hundred fifty healthy children (250 from HCMC and 200 from VL) of the same Kinh ethnicity were also analyzed as population background. In HLA class I, frequency of the HLA-A&#x0002a;24 showed increased tendency in both DHF and DSS patients, which reproduced a previous study. The frequency of A&#x0002a;24 with histidine at codon 70 (A&#x0002a;2402/03/10), based on main anchor binding site specificity analysis in DSS and DHF patients, was significantly higher than that in the population background groups (HCMC 02-03 DSS: OR&#x0200a;&#x0003d;&#x0200a;1.89, P&#x0200a;&#x0003d;&#x0200a;0.008, DHF: OR&#x0200a;&#x0003d;&#x0200a;1.75, P&#x0200a;&#x0003d;&#x0200a;0.033; VL 02-03 DSS: OR&#x0200a;&#x0003d;&#x0200a;1.70, P&#x0200a;&#x0003d;&#x0200a;0.03, DHF: OR&#x0200a;&#x0003d;&#x0200a;1.46, P&#x0200a;&#x0003d;&#x0200a;0.38; VL 04-05 DSS: OR&#x0200a;&#x0003d;&#x0200a;2.09, P&#x0200a;&#x0003d;&#x0200a;0.0075, DHF: OR&#x0200a;&#x0003d;&#x0200a;2.02, P&#x0200a;&#x0003d;&#x0200a;0.038). In HLA class II, the HLA-DRB1&#x0002a;0901 frequency was significantly decreased in secondary infection of DSS in VL 04-05 (OR&#x0200a;&#x0003d;&#x0200a;0.35, P&#x0200a;&#x0003d;&#x0200a;0.0025, Pc&#x0200a;&#x0003d;&#x0200a;0.03). Moreover, the frequency of HLA-DRB1&#x0002a;0901 in particular was significantly decreased in DSS when compared with DHF in DEN-2 infection (P&#x0200a;&#x0003d;&#x0200a;0.02).</p></sec><sec><title>Conclusion</title><p>This study improves our understanding of the risk of HLA-class I for severe outcome of DV infection in the light of peptide anchor binding site and provides novel evidence that HLA-class II may control disease severity (DHF to DSS) in DV infection.</p></sec></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Dengue has become one of the most common viral diseases transmitted by infected mosquitoes (with any of the four dengue virus serotypes: DEN-1, -2, -3, or -4). It may present as asymptomatic or illness, ranging from mild to severe disease. Recently, the severe forms, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), have become the leading cause of death among children in Southern Vietnam. The pathogenesis of DHF/DSS, however, is not yet completely understood. The immune response, virus virulence, and host genetic background are considered to be risk factors contributing to disease severity. Human leucocyte antigens (HLA) expressed on the cell surface function as antigen presenting molecules and those polymorphism can change individuals' immune response. We investigated the HLA-A, -B (class I), and -DRB1 (class II) polymorphism in Vietnamese children with different severity (DHF/DSS) by a hospital-based case-control study. The study showed persons carrying HLA-A&#x0002a;2402/03/10 are about 2 times more likely to have severe dengue infection than others. On the other hand, HLA-DRB1&#x0002a;0901 persons are less likely to develop DSS with DEN-2 virus infection. These results clearly demonstrated that HLA controlled the susceptibility to severe forms of DV infection.</p></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Dengue virus (DV) infection has become one of the most important mosquito-borne diseases in the tropics <xref ref-type="bibr" rid="pntd.0000304-Wagenaar1">&#x0005b;1&#x0005d;</xref>. An estimated 50 million people worldwide are infected with DV each year <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi1">&#x0005b;2&#x0005d;</xref>. There are two principal severe forms of DV infection, namely dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Other severe forms such as encephalitis and spastic tetraparesis occur less frequently <xref ref-type="bibr" rid="pntd.0000304-World1">&#x0005b;3&#x0005d;</xref>. Children younger than 15 years of age account for 90&#x00025; of the severe cases in Southeast Asian countries <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi2">&#x0005b;4&#x0005d;</xref> where the DHF/DSS incidence has increased about 5 fold more rapidly since 1980 than in the previous 30 years <xref ref-type="bibr" rid="pntd.0000304-World2">&#x0005b;5&#x0005d;</xref>. These severe forms of DV infection have become the leading cause of death among children in Southern Vietnam <xref ref-type="bibr" rid="pntd.0000304-Nguyen1">&#x0005b;6&#x0005d;</xref>.</p><p>Infection by any of the 4 serotypes of DV, DEN-1, -2, -3, and -4, may result in no symptoms, dengue fever (DF, without any serious complications), DHF or DSS. DF is characterized by high fever; severe headache; retro-orbital, muscle, bone or joint pains; and rash. DHF is characterized by the development of plasma leakage near the time of defervescence, thrombocytopenia, coagulation abnormalities, and hemorrhage. Hypotension with massive hemorrhage and plasma leakage characterize the most serious form of DHF called DSS <xref ref-type="bibr" rid="pntd.0000304-World1">&#x0005b;3&#x0005d;</xref>. DHF in this study corresponds to a milder form of DHF that WHO criteria define as grade I and II, and DSS to a grade III and IV DHF. The four criteria in the WHO case definition for DHF (fever, hemorrhage, thrombocytopenia and plasma leakage) were claimed not so practical because serious cases sometimes lack one or more of them, particularly hemorrhage and thrombocytopenia. Instead the Integrated Management of Childhood Illness (IMCI) has recently proposed the use of the terms &#x0201c;dengue&#x0201d; and &#x0201c;severe dengue&#x0201d; for the symptomatic patients with no emphasis on those two signs <xref ref-type="bibr" rid="pntd.0000304-World3">&#x0005b;7&#x0005d;</xref></p><p>The pathogenesis of DHF/DSS is not yet completely understood. Host immunity has been extensively analyzed, including studies of antibody-dependent enhancement (ADE) <xref ref-type="bibr" rid="pntd.0000304-Halstead1">&#x0005b;8&#x0005d;</xref>, complement activation <xref ref-type="bibr" rid="pntd.0000304-Halstead1">&#x0005b;8&#x0005d;</xref>, anti-platelet antibodies <xref ref-type="bibr" rid="pntd.0000304-Halstead1">&#x0005b;8&#x0005d;</xref>, suppressed Th1/predominant Th2 functions <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi2">&#x0005b;4&#x0005d;</xref> and the production of cytokines <xref ref-type="bibr" rid="pntd.0000304-Suharti1">&#x0005b;9&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Pang1">&#x0005b;10&#x0005d;</xref> and cytotoxic factors <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi2">&#x0005b;4&#x0005d;</xref>. Virus factor has also been studied. DEN-2 viral strains were associated with DHF/DSS in Thailand and Vietnam; DEN-3 strains have been predominant in the DHF/DSS in Sri Lanka, Indonesia and India; while in Latin America, DEN-2,-3,-4 have all been commonly associated with severe disease <xref ref-type="bibr" rid="pntd.0000304-Halstead1">&#x0005b;8&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-White1">&#x0005b;11&#x0005d;</xref>. In addition to those, still unidentified variations in immune response, virus virulence, and host genetic background are considered to be risk factors contributing to disease development <xref ref-type="bibr" rid="pntd.0000304-Wagenaar1">&#x0005b;1&#x0005d;</xref>.</p><p>Several genetic factors potentially influencing the severity of dengue infection, such as vitamin D receptor (VDR), Fc&#x003b3; receptor II (Fc&#x003b3;RII), interleukin-4 (IL-4), interleukin-1 receptor antagonist (IL-1RA), and mannose-binding lectin (MBL) were investigated in Vietnamese <xref ref-type="bibr" rid="pntd.0000304-Loke1">&#x0005b;12&#x0005d;</xref>. Among them, the T allele at position 352 of the VDR gene was associated with resistance to DSS as well as homozygotes for the arginine variant at position 131 of the Fc&#x003b3;RII gene were shown to be protective against DSS. Additionally, the G allele at position -336 of DC-SIGN (dendritic cell-specific ICAM-3 grabbing nonintegrin) was reported to be protective against DF among the Thai population <xref ref-type="bibr" rid="pntd.0000304-Sakuntabhai1">&#x0005b;13&#x0005d;</xref>.</p><p>Dengue virus, like other members of the <italic>Flaviviridae</italic> family, increases the expression of HLA class I and II molecules on infected cells <xref ref-type="bibr" rid="pntd.0000304-King1">&#x0005b;14&#x0005d;</xref>. HLA-controlled immune response may be responsible for the immunopathology of DV infection <xref ref-type="bibr" rid="pntd.0000304-King1">&#x0005b;14&#x0005d;</xref>. The host HLA allele profile influenced the reactivity of DV-specific T cells <xref ref-type="bibr" rid="pntd.0000304-Spaulding1">&#x0005b;15&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Zivna1">&#x0005b;16&#x0005d;</xref> however, there have been only a few informative studies on HLA association with the severity of DV infection <xref ref-type="bibr" rid="pntd.0000304-Loke2">&#x0005b;17&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Stephens1">&#x0005b;18&#x0005d;</xref>. In the present study, we investigated the HLA-A, HLA-B, and HLA-DRB1 polymorphisms in the Vietnamese population and the association of HLA alleles with two different clinical forms of severe DV infection during the years 2002&#x02013;2005.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study subjects</title><p>The study was performed at two hospitals, the Children's Hospital No. 2 in Ho Chi Minh City (HCMC) and the Center for Preventive Medicine in the Vinh Long Province (VL) of the Mekong Delta. The enrolment was consecutive sequence of children hospitalized at each hospital. The inclusion criteria at the entry point in the hospital were age 6 months to 15 years old, Kinh race, and unrelatedness. The subjects enrolled initially were 325, 356 and 403 in HCMC 2002&#x02013;2003 (HCMC 02-03), VL 2002-2003 (VL 02-03) and VL 2004&#x02013;2005 (VL 04-05), respectively. DV infection of the patients was diagnosed by clinical symptoms and history at the admission time. After hospitalization, the patients were diagnosed by the well established serology as described below.</p><p>WHO classification criteria <xref ref-type="bibr" rid="pntd.0000304-World1">&#x0005b;3&#x0005d;</xref> was applied after a review of case report form (CRF) of each patient. The DHF classification required fever or a history of acute fever, bleeding manifestation, and signs of plasma leakage which include hemoconcentration, ascites, or pleural effusion with evidence of thrombocytopenia. Hemoconcentration (more than 20&#x00025; increase in Hct) was evaluated by estimating the percent increase in the Hct by comparing two values recorded at 2 different timings: the maximum value in defervescence day and the value before discharge. The ascites, or pleural effusion were detected by echography or X-ray. The DSS classification required DHF manifestation plus evidence of clinical hypovolemic shock (tachycardia and narrow pulse pressure (&#x0003c;20 mmHg))</p><p>It was previously reported that the sensitivity of WHO criteria for DSS in Vietnam was 82&#x00025;, mainly due to the lack of evidence for thrombocytopenia <xref ref-type="bibr" rid="pntd.0000304-Jos1">&#x0005b;19&#x0005d;</xref>. Therefore, we basically followed the WHO criteria but included patients lacking the significant reduction of platelet count, which accounted for no more than 11&#x00025; of all DHF/DSS cases. Our classification met the requirement of the simplified classification system of IMCI, which is based on plasma leakage as a hallmark of severe dengue (DHF/DSS) <xref ref-type="bibr" rid="pntd.0000304-World3">&#x0005b;7&#x0005d;</xref>.</p><p>Healthy unrelated school children living in HCMC and VL (250 and 200 subjects respectively) who had no symptoms of dengue virus infection were collected as a background population control group for the genetic study. In these control groups, 13 cases (5.2&#x00025;) in HCMC and 16 cases (8.0&#x00025;) in VL were seropositive for IgM ELISA to DV, indicating recent asymptomatic DV infection.</p><p>This study was approved by the institutional ethical review committees of the Institute of Tropical Medicine, Nagasaki University, and the Pasteur Institute in Ho Chi Minh City. Informed consent was obtained from the parents or legal guardians of the subjects upon enrollment.</p></sec><sec id="s2b"><title>Sample collection and serological diagnosis</title><p>Blood samples were collected from patients with suspected dengue infection at the time of enrolment to the study and in the convalescent phase prior to discharge from the hospital. Plasma samples were used for titration of anti-DV IgM and IgG antibodies, virus isolation, and RT-PCR for determination of viral serotype; buffy coat samples were used to extract genomic DNA by using the QIAamp DNA blood kit (Qiagen, Hilden, Germany). DV infection was defined by previously established serologic criteria for IgM/IgG ELISAs to DV (DEN 1&#x02013;4) and Japanese encephalitis virus (kit of Pasteur Institute HCMC) in paired sera, collected at least three days interval <xref ref-type="bibr" rid="pntd.0000304-Innis1">&#x0005b;20&#x0005d;</xref>. IgM and IgG ELISAs were considered positive if the ratio of optical density (OD) of test sera to OD of negative control sera was &#x02265;2.3 <xref ref-type="bibr" rid="pntd.0000304-World1">&#x0005b;3&#x0005d;</xref>. The cases were diagnosed as secondary infection when DV IgM-to-IgG ratio was &#x0003c;1.8 <xref ref-type="bibr" rid="pntd.0000304-Innis1">&#x0005b;20&#x0005d;</xref>.</p></sec><sec id="s2c"><title>Dengue virus serotyping</title><p>Acute plasma samples were inoculated into C6/36 (<italic>Aedes albopictus</italic>) cells, the virus was then obtained and the dengue virus serotype was identified using the direct or indirect fluorescent antibody technique monoclonal antibodies supplied by the Centers for Disease Control and Prevention (Fort Collins, CO, USA) <xref ref-type="bibr" rid="pntd.0000304-Gubler1">&#x0005b;21&#x0005d;</xref>. Viral RNA was also extracted from the same acute plasma samples with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) for detection of DV and confirmation of its serotype as described <xref ref-type="bibr" rid="pntd.0000304-Gubler1">&#x0005b;21&#x0005d;</xref>. Briefly, cDNA from the DV genome RNA was amplified with the Ready-to-go RT-PCR test kit (Amersham, MA, USA) using consensus primer set (D1 and D2) <xref ref-type="bibr" rid="pntd.0000304-Lanciotti1">&#x0005b;22&#x0005d;</xref>. Then, the serotype was determined by semi-nested PCR to amplify serotype-specific fragments from the regions encoding the capsid and membrane proteins of DV using the specific primer sets (TS1, TS2, TS3, and TS4) <xref ref-type="bibr" rid="pntd.0000304-Lanciotti1">&#x0005b;22&#x0005d;</xref>.</p></sec><sec id="s2d"><title>HLA typing</title><p>HLA-A, -B and -DRB1 were typed by using LABType SSO class I A and B and class II DRB1 locus kits (One Lambda, CA, USA) and the Luminex LX 100 IS system (Hitachi, Japan). IS 2.3 typing software (Luminex Corporation, TX, USA) was used to determine the genotype. The presence of alleles of interest were confirmed by PCR with sequence-specific primers (PCR-SSP) <xref ref-type="bibr" rid="pntd.0000304-Charron1">&#x0005b;23&#x0005d;</xref> (HLA-A&#x0002a;24) and sequencing-based typing (HLA-DRB1&#x0002a;0901) &#x0005b;according to the standard protocol 10-B of the 13th International Histoconpatibility Workshop (<ext-link ext-link-type="uri" xlink:href="http://www.ihwg.org/protocols/sbt/sbtprot.htm">http://www.ihwg.org/protocols/sbt/sbtprot.htm</ext-link>)&#x0005d;. HLA-A, HLA-B, and HLA-DRB1 genotype distributions were checked with Hardy-Weinberg equilibrium.</p></sec><sec id="s2e"><title>Statistical analysis</title><p>The frequencies of individuals carrying particular alleles (phenotype frequencies) were compared between categories of the case group (DHF or DSS) and the population background group. The difference in frequency was evaluated by the odds ratio (OR) with Fisher exact 95&#x00025; confidence intervals (95&#x00025; CI), and Exact Fisher two sided P using StatsDirect statistical software, version 2.6.4. The locus-wise correction of the P value (Pc) for multiple tests was made by multiplying the P value by the number of the major alleles whose phenotype frequencies were more than 5&#x00025; in either the patient or population background group. The correction factors (CF) were 8 for HLA-A, 13 for HLA-B and 12 for HLA-DRB1. Difference yielding Pc values less than 0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>Results/Discussion</title><sec id="s3a"><title>Clinical features of the patients</title><p>Demographic and clinical features of the study subjects are shown in <xref ref-type="table" rid="pntd-0000304-t001">Table 1</xref>. An important clinical findings in this study was hepatomegaly which was clearly more prevalent in DSS than in DHF patients (in HCMC 02-03: 90.8&#x00025; vs. 47.9&#x00025;, in VL 02-03: 98.8&#x00025; vs. 88.6&#x00025;, and in VL 04-05: 93.8&#x00025; vs. 78.0&#x00025;, ORs above 4, footnote b of <xref ref-type="table" rid="pntd-0000304-t001">Table 1</xref>). There was substantial evidence of hepatomegaly in Asian patients <xref ref-type="bibr" rid="pntd.0000304-Butt1">&#x0005b;24&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Faridi1">&#x0005b;25&#x0005d;</xref> as well as in South American patients <xref ref-type="bibr" rid="pntd.0000304-DazQuijano1">&#x0005b;26&#x0005d;</xref> with DHF/DSS. Our results therefore agree with the previous study by Pham <italic>et al.</italic> which propose hepatomegaly as one of the clinical predictors of DSS in children <xref ref-type="bibr" rid="pntd.0000304-Pham1">&#x0005b;27&#x0005d;</xref>.</p><table-wrap id="pntd-0000304-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t001</object-id><label>Table 1</label><caption><title>Study subjects</title></caption><graphic id="pntd-0000304-t001-1" xlink:href="pntd.0000304.t001"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Ho Chi Minh City (HCMC)</td><td colspan="5" align="left" rowspan="1">Vinh Long province (VL)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">HCMC 02-03</td><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">VL02-03</td><td colspan="2" align="left" rowspan="1">VL04-05</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DSS</td><td align="left" rowspan="1" colspan="1">DHF</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">DSS</td><td align="left" rowspan="1" colspan="1">DHF</td><td align="left" rowspan="1" colspan="1">DSS</td><td align="left" rowspan="1" colspan="1">DHF</td><td align="left" rowspan="1" colspan="1">Control</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;152</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;117</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;250</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;170</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;35</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;96</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;59</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;200</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean age (years)&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">9.1&#x000b1;3.2</td><td align="left" rowspan="1" colspan="1">10.6&#x000b1;3.2</td><td align="left" rowspan="1" colspan="1">7.8&#x000b1;4.4</td><td align="left" rowspan="1" colspan="1">9.9&#x000b1;3.0</td><td align="left" rowspan="1" colspan="1">8.6&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">8.6&#x000b1;3.4</td><td align="left" rowspan="1" colspan="1">8.8&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">10.9&#x000b1;2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Male (&#x00025;)<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">80 (52.6)</td><td align="left" rowspan="1" colspan="1">70 (59.8)</td><td align="left" rowspan="1" colspan="1">143 (57.0)</td><td align="left" rowspan="1" colspan="1">78 (45.9)</td><td align="left" rowspan="1" colspan="1">16 (45.7)</td><td align="left" rowspan="1" colspan="1">37 (38.5)</td><td align="left" rowspan="1" colspan="1">36 (61.0)</td><td align="left" rowspan="1" colspan="1">110 (55.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatomegaly (&#x00025;) <xref ref-type="table-fn" rid="nt103">b</xref></td><td align="left" rowspan="1" colspan="1">138 (90.8)</td><td align="left" rowspan="1" colspan="1">56 (47.9)</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">168 (98.8)</td><td align="left" rowspan="1" colspan="1">31 (88.6)</td><td align="left" rowspan="1" colspan="1">90 (93.8)</td><td align="left" rowspan="1" colspan="1">46 (78.0)</td><td align="left" rowspan="1" colspan="1">nd</td></tr><tr><td align="left" rowspan="1" colspan="1">Percent increase in Hct (&#x00025;)&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">36.6&#x000b1;16.5</td><td align="left" rowspan="1" colspan="1">27.4&#x000b1;9.8</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">34.5&#x000b1;20.9</td><td align="left" rowspan="1" colspan="1">31.2&#x000b1;17.2</td><td align="left" rowspan="1" colspan="1">26&#x000b1;19.9</td><td align="left" rowspan="1" colspan="1">23.3&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">nd</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary infection (&#x00025;)<xref ref-type="table-fn" rid="nt104">c</xref></td><td align="left" rowspan="1" colspan="1">81 (53.3)</td><td align="left" rowspan="1" colspan="1">50 (42.7)</td><td align="left" rowspan="1" colspan="1">nd</td><td align="left" rowspan="1" colspan="1">95 (55.9)</td><td align="left" rowspan="1" colspan="1">13 (37.1)</td><td align="left" rowspan="1" colspan="1">80 (83.3)</td><td align="left" rowspan="1" colspan="1">46 (78.0)</td><td align="left" rowspan="1" colspan="1">nd</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, SD: standard deviation, nd: not done, P: Fisher's exact test, Hct: hematocrit.</p></fn><fn id="nt102"><label>a</label><p>Male among DSS patients in VL04-05 vs. VL controls: P&#x0200a;&#x0003d;&#x0200a;0.008</p></fn><fn id="nt103"><label>b</label><p>Hepatomegaly among DSS patients vs. DHF patients, in HCMC 02-03: OR&#x0200a;&#x0003d;&#x0200a;10.74, P&#x0003c;0.0001, in VL 02-03: OR&#x0200a;&#x0003d;&#x0200a;10.84, P&#x0200a;&#x0003d;&#x0200a;0.008, in VL 04-05:OR&#x0200a;&#x0003d;&#x0200a;4.24, P&#x0200a;&#x0003d;&#x0200a;0.005</p></fn><fn id="nt104"><label>c</label><p>Secondary infection in DSS VL04-05 vs. HCMC 02-03: P&#x0003c;0.0001, VL04-05 vs. VL02-03: P&#x0003c;0.0001 and in DHF VL04-05 vs. HCMC 02-03: P&#x0003c;0.0001, VL04-05 vs. VL02-03: P&#x0200a;&#x0003d;&#x0200a;0.0001</p></fn></table-wrap-foot></table-wrap><p>Another point of note was concerning the issue of significance of secondary infection of DV in the pathogenesis of severe cases. Although secondary infection has been reported to confer most of the risk of disease severity, it is also known that patients without evidence of secondary infection substantially contribute to severe cases in Taiwan <xref ref-type="bibr" rid="pntd.0000304-Chao1">&#x0005b;28&#x0005d;</xref> and Thailand <xref ref-type="bibr" rid="pntd.0000304-Sriprom1">&#x0005b;29&#x0005d;</xref>. Our study is similar to that study in Thailand 2003 <xref ref-type="bibr" rid="pntd.0000304-Sriprom1">&#x0005b;29&#x0005d;</xref>, where the patients with high IgM/IgG ratio consist of nearly 60&#x00025; of DSS and 40&#x00025; of DHF. The data still support the notion of disease risk associated with secondary infection (footnote c of <xref ref-type="table" rid="pntd-0000304-t001">Table 1</xref>).</p><p>It is worth to mention that four percents of our patients were under 1 year of age and all had primary DV infection. The presence of non neutralizing or low level of neutralizing maternal antibodies may play a role in the development of severe disease. Halstead <italic>et al.</italic> pointed out that infants are a high risk group for DHF/DSS, and need to be studied to further understand primary dengue infection <xref ref-type="bibr" rid="pntd.0000304-Halstead2">&#x0005b;30&#x0005d;</xref>.</p></sec><sec id="s3b"><title>DV serotypes and disease severity</title><p>Virus serotype was tested on 388 patients whose blood samples collected within five days after the onset of symptoms, mostly on days 4 and 5. As shown in <xref ref-type="table" rid="pntd-0000304-t002">Table 2</xref>, DV was identified in 87 DHF/DSS patients, which gave a detection rate of 22.4&#x00025;. This was far lower than many other studies but consistent with a previous observation that the sensitivity to detect DV is dulled in the present of neutralizing antibody <xref ref-type="bibr" rid="pntd.0000304-Innis1">&#x0005b;20&#x0005d;</xref>. Similar low detection rate was reported in Bangladesh study in 2002 <xref ref-type="bibr" rid="pntd.0000304-Islam1">&#x0005b;31&#x0005d;</xref>, where virus serotype could only be identified in 8&#x00025; of samples.</p><table-wrap id="pntd-0000304-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t002</object-id><label>Table 2</label><caption><title>Dengue virus serotypes and disease severity (2002&#x02013;05)</title></caption><graphic id="pntd-0000304-t002-2" xlink:href="pntd.0000304.t002"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Number of cases (&#x00025;)</td><td colspan="2" align="left" rowspan="1">DSS vs. DHF</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">DSS (n&#x0200a;&#x0003d;&#x0200a;43)</td><td colspan="2" align="left" rowspan="1">DHF (n&#x0200a;&#x0003d;&#x0200a;44)</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DEN-1</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">(23.3)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">(13.6)</td><td align="left" rowspan="1" colspan="1">1.90 (0.56&#x02013;7.11)</td><td align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">DEN-2</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">(70.0)</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">(45.5)</td><td align="left" rowspan="1" colspan="1">2.77 (1.05&#x02013;7.37)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">DEN-3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(7.0)</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">(22.7)</td><td align="left" rowspan="1" colspan="1">0.26 (0.04&#x02013;1.11)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">DEN-4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">(18.2)</td><td align="left" rowspan="1" colspan="1">0.05 (0.003&#x02013;0.88)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr></tbody></table><table-wrap-foot><fn id="nt105"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome</p></fn><fn id="nt106"><label/><p>OR: Odds ratio, 95&#x00025; CI: Fisher exact 95&#x00025; confidence intervals, P: Fisher's exact test</p></fn></table-wrap-foot></table-wrap><p>DEN-2 constituted the majority of the total isolates, 50 (57.5&#x00025;) followed by 16 DEN-1 (18.4&#x00025;), 13 DEN-3 (14.9&#x00025;) and 8 DEN-4 (9.2&#x00025;). The correlation between DEN-2 infection and the severe clinical forms (<xref ref-type="table" rid="pntd-0000304-t002">Table 2</xref>) provided additional proof for higher virulence of this serotype because previous study reported that patients with DEN-2 had a larger pleural effusion index than those infected by other virus serotypes <xref ref-type="bibr" rid="pntd.0000304-Vaughn1">&#x0005b;32&#x0005d;</xref>.</p></sec><sec id="s3c"><title>Phenotype frequencies of HLA-A, HLA-B and HLA-DRB1</title><p>We identified 16 HLA-A alleles, 47 HLA-B alleles and 36 HLA-DRB1 alleles in the study subjects. Major alleles (phenotype frequencies having more than 5&#x00025; in either the patient or healthy background groups) are shown in <xref ref-type="table" rid="pntd-0000304-t003">Table 3</xref> and <xref ref-type="supplementary-material" rid="pntd.0000304.s003">Table S1</xref>, accounted for about 80&#x02013;90&#x00025; of the total phenotypes. We analyzed only these major alleles for the evaluation of the risk of disease severity because rare alleles would have little impact on population risk. There were no significant difference in phenotype frequencies of the major alleles in the 2 population background groups (<xref ref-type="supplementary-material" rid="pntd.0000304.s003">Table S1</xref>), and these data were compatible with data from a previous study <xref ref-type="bibr" rid="pntd.0000304-Loke2">&#x0005b;17&#x0005d;</xref> on the same Kinh ethnic in Southern Vietnam.</p><table-wrap id="pntd-0000304-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t003</object-id><label>Table 3</label><caption><title>Major alleles of HLA-A, -B, -DRB1 in Vietnamese</title></caption><graphic id="pntd-0000304-t003-3" xlink:href="pntd.0000304.t003"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1">Allele</td><td align="left" rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HLA-A</td><td align="left" rowspan="1" colspan="1">&#x0002a;01, &#x0002a;02, &#x0002a;11, &#x0002a;24, &#x0002a;26, &#x0002a;29, &#x0002a;30, &#x0002a;33</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">HLA-B</td><td align="left" rowspan="1" colspan="1">&#x0002a;07, &#x0002a;13, &#x0002a;15, &#x0002a;27, &#x0002a;35, &#x0002a;38, &#x0002a;40, &#x0002a;44, &#x0002a;46, &#x0002a;51, &#x0002a;55, &#x0002a;57, &#x0002a;58</td><td align="left" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">HLA-DRB1</td><td align="left" rowspan="1" colspan="1">&#x0002a;0301, &#x0002a;0403, &#x0002a;0405, &#x0002a;0701, &#x0002a;0803, &#x0002a;0901, &#x0002a;1001, &#x0002a;1202, &#x0002a;1401, &#x0002a;1501, &#x0002a;1502 &#x0002a;1602</td><td align="left" rowspan="1" colspan="1">12</td></tr></tbody></table></table-wrap></sec><sec id="s3d"><title>HLA-A&#x0002a;24 was positively associated with DSS or DHF</title><p>As shown in <xref ref-type="table" rid="pntd-0000304-t004">Table 4</xref> and <xref ref-type="table" rid="pntd-0000304-t005">5</xref>, HLA-A&#x0002a;24 increased in frequency among DHF and DSS patients when compared with the control in all 3 sample groups, HCMC 02-03 (DSS: OR&#x0200a;&#x0003d;&#x0200a;1.62, P&#x0200a;&#x0003d;&#x0200a;0.04, Pc&#x0200a;&#x0003d;&#x0200a;0.3; DHF: OR&#x0200a;&#x0003d;&#x0200a;1.35, P&#x0200a;&#x0003d;&#x0200a;0.26), VL 02-03 (DSS: OR&#x0200a;&#x0003d;&#x0200a;1.51, P&#x0200a;&#x0003d;&#x0200a;0.08; DHF: OR&#x0200a;&#x0003d;&#x0200a;1.34, P&#x0200a;&#x0003d;&#x0200a;0.4), and VL 04-05 (DSS: OR&#x0200a;&#x0003d;&#x0200a;1.80, P&#x0200a;&#x0003d;&#x0200a;0.029, Pc&#x0200a;&#x0003d;&#x0200a;0.2; DHF: OR&#x0200a;&#x0003d;&#x0200a;2.71, P&#x0200a;&#x0003d;&#x0200a;0.0019, Pc&#x0200a;&#x0003d;&#x0200a;0.02).</p><table-wrap id="pntd-0000304-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t004</object-id><label>Table 4</label><caption><title>Phenotype frequencies of HLA-A&#x0002a;24 and HLA-DRB1&#x0002a;0901 in primary and secondary infection and population background groups</title></caption><graphic id="pntd-0000304-t004-4" xlink:href="pntd.0000304.t004"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1">Phenotype</td><td colspan="6" align="left" rowspan="1">HCMC</td><td colspan="10" align="left" rowspan="1">VL</td></tr><tr><td colspan="3" align="left" rowspan="1"/><td colspan="6" align="left" rowspan="1">HCMC 02-03</td><td colspan="4" align="left" rowspan="1">VL 02-03</td><td colspan="4" align="left" rowspan="1">VL 04-05</td><td colspan="2" align="left" rowspan="1"/></tr><tr><td colspan="3" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">Control</td><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">Control</td></tr><tr><td colspan="3" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td></tr></thead><tbody><tr><td colspan="19" align="left" rowspan="1">1. HLA-A&#x0002a;24</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">A&#x0002a;24</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">(34.9)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">(30.8)</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">(24.8)</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">(33.5)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(31.4)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">(37.5)</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">(47.5)</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">(25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">A&#x0002a;24 Primary infection</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">(39.4)</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">(37.3)</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">(24.8)</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">(37.3)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">(36.4)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(18.8)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">(58.3)</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">(25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">A&#x0002a;24 Secondary infection</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">(30.9)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(22.0)</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">(24.8)</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">(30.5)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(23.0)</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">(41.3)</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">(45.7)</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">(25.0)</td></tr><tr><td colspan="19" align="left" rowspan="1">2. HLA- DRB1&#x0002a;0901</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">(21.7)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">(26.5)</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">(24.4)</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">(20.6)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">(17.1)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">(14.6)</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">(25.4)</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">(31.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 Primary infection</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">(21.1)</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(26.9)</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">(24.4)</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">(22.7)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(9.1)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(18.8)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(33.3)</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">(31.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 Secondary infection</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(22.2)</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">(26.0)</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">(24.4)</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(18.9)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(30.8)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(13.8)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(23.9)</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">(31.5)</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd-0000304-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t005</object-id><label>Table 5</label><caption><title>Association of HLA-A&#x0002a;24, -DRB1&#x0002a;0901 allele with severe forms</title></caption><graphic id="pntd-0000304-t005-5" xlink:href="pntd.0000304.t005"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="3" align="left" rowspan="1"/><td colspan="3" align="left" rowspan="1">HCMC</td><td colspan="6" align="left" rowspan="1">VL</td></tr><tr><td colspan="3" align="left" rowspan="1"/><td colspan="3" align="left" rowspan="1">HCMC 02-03</td><td colspan="3" align="left" rowspan="1">VL 02-03</td><td colspan="3" align="left" rowspan="1">VL 04-05</td></tr><tr><td colspan="3" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Pc</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Pc</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Pc</td></tr></thead><tbody><tr><td colspan="12" align="left" rowspan="1">1. HLA- A&#x0002a;24</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">DSS vs. control</td><td align="left" rowspan="1" colspan="1">1.62 (1.02&#x02013;2.58)</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">1.51 (0.94&#x02013;2.44)</td><td align="left" rowspan="1" colspan="1">0.084</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.80 (1.03&#x02013;3.13)</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">DSS with primary infection vs. controls</td><td align="left" rowspan="1" colspan="1">1.97 (1.08&#x02013;3.56)</td><td align="left" rowspan="1" colspan="1">0.024</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">2.38 (1.30&#x02013;4.32)</td><td align="left" rowspan="1" colspan="1">0.0032</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.69 (0.12&#x02013;2.67)</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">DSS with secondary infection vs. controls</td><td align="left" rowspan="1" colspan="1">1.35 (0.74&#x02013;2.42)</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.76 (0.99&#x02013;3.09)</td><td align="left" rowspan="1" colspan="1">0.045</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">2.11 (1.17&#x02013;3.77)</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">DHF vs. control</td><td align="left" rowspan="1" colspan="1">1.35 (0.80&#x02013;2.25)</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.34 (0.57&#x02013;3.16)</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2.71 (1.41&#x02013;5.16)</td><td align="left" rowspan="1" colspan="1">0.0019</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">DHF with primary infection vs. controls</td><td align="left" rowspan="1" colspan="1">1.13 (0.63&#x02013;2.00)</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2.29 (0.78&#x02013;6.20)</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">4.2 (1.08&#x02013;17.43)</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">DHF with secondary infection vs. controls</td><td align="left" rowspan="1" colspan="1">0.86 (0.37&#x02013;1.83)</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.20 (0.20&#x02013;4.89)</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2.52 (1.22&#x02013;5.13)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">DSS vs. DHF</td><td align="left" rowspan="1" colspan="1">1.20 (0.70&#x02013;2.09)</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.1 (0.48&#x02013;2.67)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.66 (0.33&#x02013;1.35)</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td colspan="12" align="left" rowspan="1">2. HLA- DRB1&#x0002a;0901</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">DSS vs. control</td><td align="left" rowspan="1" colspan="1">0.86 (0.51&#x02013;1.42)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.56 (0.34&#x02013;0.93)</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.37 (0.18&#x02013;0.72)</td><td align="left" rowspan="1" colspan="1">0.0018</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">DSS with primary infection vs. controls</td><td align="left" rowspan="1" colspan="1">0.83 (0.41&#x02013;1.62)</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.64 (0.32&#x02013;1.22)</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.50 (0.09&#x02013;1.92)</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">DSS with secondary infection vs. controls</td><td align="left" rowspan="1" colspan="1">0.89 (0.46&#x02013;1.66)</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.51 (0.26&#x02013;0.95)</td><td align="left" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">0.35 (0.16&#x02013;0.72)</td><td align="left" rowspan="1" colspan="1">0.0025</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">DHF vs. control</td><td align="left" rowspan="1" colspan="1">1.12 (0.65&#x02013;1.90)</td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.45 (0.15&#x02013;1.18)</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.74 (0.36&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">DHF with primary infection vs. controls</td><td align="left" rowspan="1" colspan="1">1.14 (0.58&#x02013;2.17)</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.22 (0.02&#x02013;0.95)</td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">1.09 (0.23&#x02013;4.24)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">DHF with secondary infection vs. controls</td><td align="left" rowspan="1" colspan="1">1.09 (0.50&#x02013;2.26)</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.97 (0.21&#x02013;3.63)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.68 (0.29&#x02013;1.49)</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">DSS vs. DHF</td><td align="left" rowspan="1" colspan="1">0.77 (0.42&#x02013;1.41)</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1.25 (0.46&#x02013;3.98)</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">0.50 (0.20&#x02013;1.23)</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="nt108"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, OR: Odds ratio, 95&#x00025; CI: Fisher exact 95&#x00025; confidence intervals, P: Fisher's exact test, Pc: corrected P.</p></fn></table-wrap-foot></table-wrap><p>Certain alleles of the HLA-class I genes were previously found to be associated with DHF or DSS <xref ref-type="bibr" rid="pntd.0000304-Wagenaar1">&#x0005b;1&#x0005d;</xref>. In a study of Thai patients, Stephens <italic>et al.</italic> found that HLA- A&#x0002a;0207 and HLA-B&#x0002a;51 were susceptible to both DHF and DSS <xref ref-type="bibr" rid="pntd.0000304-Stephens1">&#x0005b;18&#x0005d;</xref>. It was also reported that HLA-A&#x0002a;29 and A&#x0002a;33 were protective against DHF and DSS in Cuban <xref ref-type="bibr" rid="pntd.0000304-ParadoaPerez1">&#x0005b;33&#x0005d;</xref> and in Vietnamese patients, respectively <xref ref-type="bibr" rid="pntd.0000304-Loke2">&#x0005b;17&#x0005d;</xref>. The inconsistency of these HLA associations may be the result of the differences in ethnicity, geographic location or the diversity of the predominant virus during the study periods <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi1">&#x0005b;2&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-BeatrizSierra1">&#x0005b;34&#x0005d;</xref>.</p><p>The results of HLA class I association from the present study reproduced a previous Vietnamese study (309 cases and 251 controls) by Loke <italic>et al.</italic> in which HLA-A&#x0002a;24 association with DHF and DSS was found, with OR 1.54 and P value 0.021 <xref ref-type="bibr" rid="pntd.0000304-Loke2">&#x0005b;17&#x0005d;</xref>. Considering such reproducibility in different study periods, within the same ethnic group and in the same region, give us the confidence to assign an association of HLA-A&#x0002a;24 and DHF, DSS even though our P value just reached the significant level before Bonferoni correction.</p></sec><sec id="s3e"><title>HLA-A&#x0002a;24 with Histidine at codon 70 was positively associated with DSS and DHF</title><p>It is known that HLA-A&#x0002a;24 alleles fall into at least two subtypes by the difference at codon 70 of alpha 1 domain, which together with codons 9, 45, 63, 66 and 67 composes peptide binding pocket B for P2 anchor position <xref ref-type="bibr" rid="pntd.0000304-Sidney1">&#x0005b;35&#x0005d;</xref>. In the present study, there were 4 different A&#x0002a;24 alleles, A&#x0002a;2402, A&#x0002a;2403, A&#x0002a;2407 and A&#x0002a;2410 (<xref ref-type="table" rid="pntd-0000304-t006">Table 6</xref>). A&#x0002a;2407 is different from the others at codon 70 where histidine (CAC) is changed to glutamine (CAG). The frequencies of A&#x0002a;24 with histidine at codon 70 in DSS and DHF patients were significantly higher than that in the population background groups (HCMC 02-03 DSS: OR&#x0200a;&#x0003d;&#x0200a;1.89, P&#x0200a;&#x0003d;&#x0200a;0.008, DHF: OR&#x0200a;&#x0003d;&#x0200a;1.75, P&#x0200a;&#x0003d;&#x0200a;0.03; VL 02-03 DSS: OR&#x0200a;&#x0003d;&#x0200a;1.70, P&#x0200a;&#x0003d;&#x0200a;0.03, DHF OR&#x0200a;&#x0003d;&#x0200a;1.46, P&#x0200a;&#x0003d;&#x0200a;0.38; VL 04-05 DSS: OR&#x0200a;&#x0003d;&#x0200a;2.09, P&#x0200a;&#x0003d;&#x0200a;0.0075, DHF OR&#x0200a;&#x0003d;&#x0200a;2.02, P&#x0200a;&#x0003d;&#x0200a;0.038, <xref ref-type="table" rid="pntd-0000304-t007">Table 7</xref>). On the other hand, A&#x0002a;24 with glutamine at codon 70, A&#x0002a;2407 in our samples, did not show any significant difference in frequency (<xref ref-type="table" rid="pntd-0000304-t006">Table 6</xref>). Similar behavior of this allele was documented in Indian HIV study <xref ref-type="bibr" rid="pntd.0000304-Umapathy1">&#x0005b;36&#x0005d;</xref>.</p><table-wrap id="pntd-0000304-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t006</object-id><label>Table 6</label><caption><title>Phenotype frequencies of HLA-A&#x0002a;24 subgroups</title></caption><graphic id="pntd-0000304-t006-6" xlink:href="pntd.0000304.t006"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t006-6"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">A&#x0002a;24</td><td colspan="6" align="left" rowspan="1">HCMC</td><td colspan="10" align="left" rowspan="1">VL</td></tr><tr><td colspan="2" align="left" rowspan="1"/><td colspan="4" align="left" rowspan="1">HCMC 02-03</td><td colspan="2" align="left" rowspan="1"/><td colspan="4" align="left" rowspan="1">VL 02-03</td><td colspan="4" align="left" rowspan="1">VL 04-05</td><td colspan="2" align="left" rowspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1"/><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">Control</td><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">DSS</td><td colspan="2" align="left" rowspan="1">DHF</td><td colspan="2" align="left" rowspan="1">Control</td></tr><tr><td colspan="2" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td></tr></thead><tbody><tr><td colspan="18" align="left" rowspan="1">1. A&#x0002a;24 with histidine at codon 70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0002a;2402</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">(30.3)</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">(29.1)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">(17.2)</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">(31.2)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">(22.9)</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">(35.4)</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(30.5)</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">(19.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0002a;2403</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(0.9)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(0.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(0.6)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(2.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.0)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(3.4)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0002a;2410</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(0.8)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(2.9)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">(0.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.7)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">(31.6)</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">(29.9)</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">(19.6)</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">(31.8)</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">(28.6)</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">(35.5)</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">(35.6)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">(21.5)</td></tr><tr><td colspan="18" align="left" rowspan="1">2. A&#x0002a;24 with glutamine at codon 70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A&#x0002a;2407</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">(3.3)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(1.7)</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">(5.2)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(1.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(2.9)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.0)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">(11.9)</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">(4.5)</td></tr></tbody></table><table-wrap-foot><fn id="nt109"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd-0000304-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t007</object-id><label>Table 7</label><caption><title>Association of HLA-A&#x0002a;24 with histidine at codon 70 and severe forms of DV infection</title></caption><graphic id="pntd-0000304-t007-7" xlink:href="pntd.0000304.t007"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t007-7"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">HCMC</td><td colspan="4" align="left" rowspan="1">VL</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">HCMC 02-03</td><td colspan="2" align="left" rowspan="1">VL 02-03</td><td colspan="2" align="left" rowspan="1">VL 04-05</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">P</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DSS vs. control</td><td align="left" rowspan="1" colspan="1">1.89 (1.16&#x02013;3.09)</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">1.70 (1.04&#x02013;2.79)</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">2.09 (1.18&#x02013;3.70)</td><td align="left" rowspan="1" colspan="1">0.0075</td></tr><tr><td align="left" rowspan="1" colspan="1">DHF vs. control</td><td align="left" rowspan="1" colspan="1">1.75 (1.02&#x02013;2.98)</td><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1">1.46 (0.58&#x02013;3.44)</td><td align="left" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1">2.02 (1.01&#x02013;3.95)</td><td align="left" rowspan="1" colspan="1">0.038</td></tr></tbody></table><table-wrap-foot><fn id="nt110"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, OR: Odds ratio, 95&#x00025; CI: Fisher exact 95&#x00025; confidence intervals, P: Fisher's exact test. This analysis was perform after the confirmation of A<sup>&#x0002a;</sup>24 association, so that the correction of P value did not apply.</p></fn></table-wrap-foot></table-wrap><p>The association of HLA-A&#x0002a;24 in the VL 04-05 samples was stronger than in VL 02-03 and HCMC 02-03, possibly due to higher secondary infection rate in the VL 04-05 samples. Memory T cells might be important in the A&#x0002a;24 associated pathogenesis of DHF/DSS. HLA-A&#x0002a;24 is reported to be one of the potential restricting alleles for NS3 dengue viral protein and CTLs recognizing NS3 peptides coupled with HLA-A&#x0002a;24 were cross-reactive between serotypes because NS3 is highly conserved <xref ref-type="bibr" rid="pntd.0000304-Mathew1">&#x0005b;37&#x0005d;</xref>. Two previous Vietnamese studies reported an identification of the DEN-2 NS3 556&#x02013;564 peptide that was restricted by HLA-A&#x0002a;24 <xref ref-type="bibr" rid="pntd.0000304-Loke2">&#x0005b;17&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Simmons1">&#x0005b;38&#x0005d;</xref>, but further study is needed to clarify the role of A&#x0002a;24-restricted CD8 T-cells in the pathogenesis of DHF/DSS.</p></sec><sec id="s3f"><title>HLA-DRB1&#x0002a;0901 was negatively associated with DSS</title><p>As shown in <xref ref-type="table" rid="pntd-0000304-t004">Table 4</xref> and <xref ref-type="table" rid="pntd-0000304-t005">5</xref>, the HLA-DRB1&#x0002a;0901 allele significantly decreased in frequency in DSS patients in VL 04-05 (OR&#x0200a;&#x0003d;&#x0200a;0.37, P&#x0200a;&#x0003d;&#x0200a;0.0018, Pc&#x0200a;&#x0003d;&#x0200a;0.02) when compared to the control, mainly in secondary infection (OR&#x0200a;&#x0003d;&#x0200a;0.35, P&#x0200a;&#x0003d;&#x0200a;0.0025, Pc&#x0200a;&#x0003d;&#x0200a;0.03), not in primary infection. This trend was also observed in the other 2 groups of samples but did not reach statistical significance (VL 02-03: OR 0.51, P&#x0200a;&#x0003d;&#x0200a;0.026, Pc&#x0200a;&#x0003d;&#x0200a;0.3; HCMC 02-03: OR&#x0200a;&#x0003d;&#x0200a;0.89, P&#x0200a;&#x0003d;&#x0200a;0.77).</p><p>Certain HLA class II alleles have been reported to confer a protective effect in infections of human immunodefiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) <xref ref-type="bibr" rid="pntd.0000304-Maureen1">&#x0005b;39&#x0005d;</xref>. In dengue virus infection, protective DRB1&#x0002a;07 and DRB1&#x0002a;04 alleles were recently reported. DRB1&#x0002a;07 was protective against DF, DHF and DSS and DRB1&#x0002a;04 was protective against secondary DF in Cuban population <xref ref-type="bibr" rid="pntd.0000304-BeatrizSierra1">&#x0005b;34&#x0005d;</xref>, DHF or DSS in Mexican population <xref ref-type="bibr" rid="pntd.0000304-LaFleur1">&#x0005b;40&#x0005d;</xref>. Possibly there is a common primary associated gene closely located to DRB1 locus, such as HLA-DQB1 and HLA-DRB4, for those alleles (DRB1&#x0002a;07 and DRB1&#x0002a;04) and Vietnamese DRB1&#x0002a;0901. One of the most frequent haplotypes among Oriental populations (including Kinh ethnic) is DRB1&#x0002a;0901-DQB1&#x0002a;030302. DQB1&#x0002a;030302 is also reported to be in disequilibrium with DRB1&#x0002a;0701 <xref ref-type="bibr" rid="pntd.0000304-Charron2">&#x0005b;41&#x0005d;</xref>, however there was no reduced frequency of DRB1&#x0002a;0701 in DSS patients compared to controls in our data. Furthermore, haplotypes found in South America are DRB1&#x0002a;0701-DQB1&#x0002a;0201 and HLA-DRB1&#x0002a;0403-DQB1&#x0002a;0302, not DQB1&#x0002a;030302, which suggests that the association of these protective alleles could not be elucidated by a common DQB1 allele. The possibility of primary disease-protective association with DRB4&#x0002a;01 (encoding DR53 sero-specificity) remains to be examined because of DRB4&#x0002a;01 haplotypic association with DRB1&#x0002a;07, &#x0002a;04 and &#x0002a;0901 was found in all populations which have been studied <xref ref-type="bibr" rid="pntd.0000304-Burdett1">&#x0005b;42&#x0005d;</xref>, although neither DRB1&#x0002a;07 or DRB1&#x0002a;04 exhibited difference in frequency in our samples.</p></sec><sec id="s3g"><title>Protective effect of HLA-DRB1&#x0002a;0901 against DSS development from DHF was evident when having DEN-2 infection</title><p>To see the effect of virus serotype on the HLA susceptibility, we analyzed the HLA alleles in the DEN-2-positive patients and those that were positive for DEN-1, DEN-3, or DEN-4 (DEN-2-negative). As shown in <xref ref-type="table" rid="pntd-0000304-t008">Table 8</xref>, HLA-DRB1&#x0002a;0901 frequency was significantly decreased in DSS compared with DHF among DEN-2- positive patients (OR&#x0200a;&#x0003d;&#x0200a;0.13, P&#x0200a;&#x0003d;&#x0200a;0.02). The effect of DRB1&#x0002a;0901 appeared to be DEN-2 specific because DEN-2-negative population did not show significant difference, although this may be due to the small sample size as Breslow-Day statistic for the uniformity of odds ratio did not reach significant level (P&#x0200a;&#x0003d;&#x0200a;0.14).</p><table-wrap id="pntd-0000304-t008" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000304.t008</object-id><label>Table 8</label><caption><title>Phenotype frequency of HLA- DRB1&#x0002a;0901 allele in DHF or DSS patients with DEN-2 or other serotypes</title></caption><graphic id="pntd-0000304-t008-8" xlink:href="pntd.0000304.t008"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000304-t008-8"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Serotype</td><td align="left" rowspan="1" colspan="1">DSS</td><td align="left" rowspan="1" colspan="1">DHF</td><td align="left" rowspan="1" colspan="1">DSS vs. DHF</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No. (&#x00025;)</td><td align="left" rowspan="1" colspan="1">No. (&#x00025;)</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DEN-2 (&#x0002b;)</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;30</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;20</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 (&#x0002b;)</td><td align="left" rowspan="1" colspan="1">2 (6.7)</td><td align="left" rowspan="1" colspan="1">7 (35.0)</td><td align="left" rowspan="1" colspan="1">0.13 (0.01&#x02013;0.86)</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 (&#x02212;)</td><td align="left" rowspan="1" colspan="1">28 (93.3)</td><td align="left" rowspan="1" colspan="1">13 (65.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DEN-2 (&#x02212;)</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;13</td><td align="left" rowspan="1" colspan="1">n&#x0200a;&#x0003d;&#x0200a;24</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 (&#x0002b;)</td><td align="left" rowspan="1" colspan="1">3 (23.1)</td><td align="left" rowspan="1" colspan="1">7 (29.2)</td><td align="left" rowspan="1" colspan="1">0.73 (0.10&#x02013;4.22)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">DRB1&#x0002a;0901 (&#x02212;)</td><td align="left" rowspan="1" colspan="1">10 (76.9)</td><td align="left" rowspan="1" colspan="1">17 (70.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt111"><label/><p>DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome,</p></fn><fn id="nt112"><label/><p>DEN-2 (&#x02212;): consisted of DEN-1, DEN-3, and DEN-4 as shown in <xref ref-type="table" rid="pntd-0000304-t002">Table 2</xref>.</p></fn><fn id="nt113"><label/><p>OR: Odds ratio, 95&#x00025;CI: Fisher exact 95&#x00025; confidence intervals, P: Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><p>The HLA-DRB1&#x0002a;0901 allele has also been reported at higher frequency in noncirrhotic HCV patients than in patients with cirrhosis <xref ref-type="bibr" rid="pntd.0000304-Tokushige1">&#x0005b;43&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000304-Aikawa1">&#x0005b;44&#x0005d;</xref>, suggesting protective effect of this allele against tissue destruction and disease progression. Here, when we focus on DEN-2 infection, a higher frequency of HLA-DRB1&#x0002a;0901 in DHF than in DSS patients was found. The protective effect of this allele against DSS development from DHF could be considered as a new finding in dengue infection. It is generally believed that DSS is preventable by intense clinical management, in fact a certain number of patients, however fall to shock in spite of the early efforts of physicians. Although the pathogenesis of DHF/DSS is still unclear, clinical studies have suggested that the host immune response shifted to Th2 dominant in most DSS cases <xref ref-type="bibr" rid="pntd.0000304-Chaturvedi3">&#x0005b;45&#x0005d;</xref>. Because HLA class II polymorphism can direct the antigen-specific T-cell response, it is probable that patients with HLA-DRB1&#x0002a;0901 may be prevented from the shift toward Th2 dominance. Further studies are needed to clarify this point.</p><p>In conclusion, our study confirmed the previous reported HLA association between HLA-A&#x0002a;24 and DHF or DSS and moreover showed that A&#x0002a;24 with Histidine at codon 70 to be susceptible to DSS and DHF, and HLA-DRB1&#x0002a;0901 to be protective against the development of DSS, particularly in patients with DEN-2 infection. This study represents another attempt to improve our understanding of the risk of HLA-class I for severe outcome of DV infection in the light of peptide anchor binding site and provides a novel evidence that HLA-class II may control disease severity (DHF to DSS) in DV infection.</p></sec></sec><sec sec-type="supplementary-material" id="s4"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pntd.0000304.s001"><label>Alternative Language Abstract S1</label><caption><p>Translation of the Abstract into Japanese by Kenji Hirayama</p><p>(0.09 MB PDF)</p></caption><media xlink:href="pntd.0000304.s001.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0000304.s002"><label>Alternative Language Abstract S2</label><caption><p>Translation of the Abstract into Vietnamese by Nguyen Thi Phuong Lan</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pntd.0000304.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0000304.s003"><label>Table S1</label><caption><p>Phenotype frequencies of HLA-A, HLA-B and HLA-DRB1 alleles</p><p>(0.17 MB DOC)</p></caption><media xlink:href="pntd.0000304.s003.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors express their appreciation to the Drs. Nguyen Thi Kim Tien, Duane J. Gubler, and Anavaj Sakuntabhai for continuous support and helpful discussion; and to all the members of Laboratory of Arbovirus, Pasteur Institute, Ho Chi Minh City, for their laboratory help.</p></ack><ref-list><title>References</title><ref id="pntd.0000304-Wagenaar1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagenaar</surname><given-names>JFP</given-names></name><name><surname>Mairuhu</surname><given-names>ATA</given-names></name><name><surname>van Gorp</surname><given-names>ECM</given-names></name></person-group><year>2004</year><article-title>Genetic influences on dengue virus infections.</article-title><source>Dengue Bulletin</source><volume>28</volume><fpage>126</fpage><lpage>134</lpage></citation></ref><ref id="pntd.0000304-Chaturvedi1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>U</given-names></name><name><surname>Nagar</surname><given-names>R</given-names></name><name><surname>Shrivastava</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Dengue and dengue haemorrhagic fever: implications of host genetics.</article-title><source>FEMS Immunol Med Mic</source><volume>47</volume><fpage>155</fpage><lpage>166</lpage></citation></ref><ref id="pntd.0000304-World1"><label>3</label><citation citation-type="journal"><collab>World Health Organization</collab><year>1997</year><article-title>Dengue hemorrhagic fever: diagnosis, treatment, prevention, and control.</article-title><source>Geneva</source><fpage>1</fpage><lpage>11</lpage></citation></ref><ref id="pntd.0000304-Chaturvedi2"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>UC</given-names></name><name><surname>Nagar</surname><given-names>R</given-names></name><name><surname>Shrivastava</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Macrophage and dengue virus: Friend or foe?</article-title><source>Indian J Med Res</source><volume>124</volume><fpage>23</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16926454</pub-id></citation></ref><ref id="pntd.0000304-World2"><label>5</label><citation citation-type="other"><collab>World Health Organization</collab><year>1999</year><article-title>Prevention and control of dengue and dengue hemorrhagic fever: comprehensive guidelines. WHO Regional publication, SEARO No. 29.</article-title></citation></ref><ref id="pntd.0000304-Nguyen1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TKT</given-names></name></person-group><year>2004</year><article-title>Annual report of National program for dengue control in Vietnam.</article-title></citation></ref><ref id="pntd.0000304-World3"><label>7</label><citation citation-type="journal"><collab>World Health Organization</collab><year>2005</year><article-title>Dengue, dengue haemorrhagic fever and dengue shock syndrome in the context of the integrated management of childhood illness.</article-title><source>WHO/FCH/CAH/05.13</source></citation></ref><ref id="pntd.0000304-Halstead1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group><year>2007</year><article-title>Dengue.</article-title><source>Lancet</source><volume>370</volume><fpage>1644</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17993365</pub-id></citation></ref><ref id="pntd.0000304-Suharti1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suharti</surname><given-names>C</given-names></name><name><surname>van Gorp</surname><given-names>EC</given-names></name><name><surname>Dolmans</surname><given-names>WM</given-names></name><name><surname>Setiati</surname><given-names>TE</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><etal/></person-group><year>2003</year><article-title>Cytokine patterns during dengue shock syndrome.</article-title><source>Eur Cytokine Netw</source><volume>14</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">14656693</pub-id></citation></ref><ref id="pntd.0000304-Pang1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>T</given-names></name><name><surname>Cardosa</surname><given-names>MJ</given-names></name><name><surname>Guzman</surname><given-names>MG</given-names></name></person-group><year>2007</year><article-title>Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).</article-title><source>Immunol Cell Biol</source><volume>85</volume><fpage>43</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17130899</pub-id></citation></ref><ref id="pntd.0000304-White1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><year>1999</year><article-title>Variation in virulence of dengue virus.</article-title><source>Lancet</source><volume>354</volume><fpage>1401</fpage><lpage>1402</lpage><pub-id pub-id-type="pmid">10543660</pub-id></citation></ref><ref id="pntd.0000304-Loke1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loke</surname><given-names>H</given-names></name><name><surname>Bethell</surname><given-names>D</given-names></name><name><surname>Phuong</surname><given-names>CXT</given-names></name><name><surname>Day</surname><given-names>N</given-names></name><name><surname>White</surname><given-names>N</given-names></name><etal/></person-group><year>2002</year><article-title>Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin D receptor and Fc gamma receptor IIa genes.</article-title><source>Am J Trop Med Hyg</source><volume>67</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">12363051</pub-id></citation></ref><ref id="pntd.0000304-Sakuntabhai1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakuntabhai</surname><given-names>A</given-names></name><name><surname>Turbpaiboon</surname><given-names>C</given-names></name><name><surname>Casademont</surname><given-names>I</given-names></name><name><surname>Chuansumrit</surname><given-names>A</given-names></name><name><surname>Lowhnoo</surname><given-names>T</given-names></name><etal/></person-group><year>2005</year><article-title>A variant in the CD209 promoter is associated with severity of dengue disease.</article-title><source>Nat Genet</source><volume>37</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">15838506</pub-id></citation></ref><ref id="pntd.0000304-King1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>NJ</given-names></name><name><surname>Shrestha</surname><given-names>B</given-names></name><name><surname>Kesson</surname><given-names>AM</given-names></name></person-group><year>2003</year><article-title>Immune modulation by flaviviruses.</article-title><source>Adv Virus Res</source><volume>60</volume><fpage>121</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">14689693</pub-id></citation></ref><ref id="pntd.0000304-Spaulding1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spaulding</surname><given-names>AC</given-names></name><name><surname>Kurane</surname><given-names>I</given-names></name><name><surname>Ennis</surname><given-names>FA</given-names></name><name><surname>Rothman</surname><given-names>AL</given-names></name></person-group><year>1999</year><article-title>Analysis of murine CD8&#x0002b;T-cell clones specific for the Dengue virus NS3 protein: flavivirus crossreactivity and influence of infecting serotype.</article-title><source>J Virol</source><volume>73</volume><fpage>398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">9847344</pub-id></citation></ref><ref id="pntd.0000304-Zivna1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zivna</surname><given-names>I</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Kalayanarooj</surname><given-names>S</given-names></name><name><surname>Stephens</surname><given-names>HA</given-names></name><etal/></person-group><year>2002</year><article-title>T cell responses to an HLA-B&#x0002a;07-restricted epitope on the dengue NS3 protein correlate with disease severity.</article-title><source>J Immunol</source><volume>168</volume><fpage>5959</fpage><lpage>5965</lpage><pub-id pub-id-type="pmid">12023403</pub-id></citation></ref><ref id="pntd.0000304-Loke2"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loke</surname><given-names>H</given-names></name><name><surname>Bethell</surname><given-names>DB</given-names></name><name><surname>Phuong</surname><given-names>CX</given-names></name><name><surname>Dung</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?</article-title><source>J Infect Dis</source><volume>184</volume><fpage>1369</fpage><lpage>1373</lpage><pub-id pub-id-type="pmid">11709777</pub-id></citation></ref><ref id="pntd.0000304-Stephens1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>HA</given-names></name><name><surname>Klaythong</surname><given-names>R</given-names></name><name><surname>Sirikong</surname><given-names>M</given-names></name><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais.</article-title><source>Tissue Antigens</source><volume>60</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">12472660</pub-id></citation></ref><ref id="pntd.0000304-Jos1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jos&#x000e9;</surname><given-names>G</given-names></name><name><surname>Rigau-P&#x000e9;rez</surname></name></person-group><year>2006</year><article-title>Severe dengue: the need for new case definitions.</article-title><source>Lancet Infect Dis</source><volume>6</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">16631550</pub-id></citation></ref><ref id="pntd.0000304-Innis1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Innis</surname><given-names>BL</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><name><surname>Nimmannitva</surname><given-names>S</given-names></name><name><surname>Kusalerdchariya</surname><given-names>S</given-names></name><name><surname>Chongswasdi</surname><given-names>V</given-names></name><etal/></person-group><year>1989</year><article-title>An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate.</article-title><source>Am J Trop Med Hyg</source><volume>40</volume><fpage>418</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">2540664</pub-id></citation></ref><ref id="pntd.0000304-Gubler1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gubler</surname><given-names>DJ</given-names></name><name><surname>Kuno</surname><given-names>G</given-names></name><name><surname>Sather</surname><given-names>GE</given-names></name><name><surname>Valez</surname><given-names>M</given-names></name><name><surname>Oliver</surname><given-names>A</given-names></name></person-group><year>1984</year><article-title>Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses.</article-title><source>Am J Trop Med Hyg</source><volume>33</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">6364855</pub-id></citation></ref><ref id="pntd.0000304-Lanciotti1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanciotti</surname><given-names>RS</given-names></name><name><surname>Calisher</surname><given-names>CH</given-names></name><name><surname>Gubler</surname><given-names>DJ</given-names></name><name><surname>Chang</surname><given-names>GJ</given-names></name><name><surname>Vorndam</surname><given-names>AV</given-names></name></person-group><year>1992</year><article-title>Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction.</article-title><source>J Clin Microbiol</source><volume>30</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">1372617</pub-id></citation></ref><ref id="pntd.0000304-Charron1"><label>23</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Charron</surname><given-names>D</given-names></name></person-group><year>1997</year><article-title>12<sup>th</sup> International Histocompatibility Workshop and Conference Proceedings: Genetic Diversity of HLA: Functional and Medical Implications.</article-title><person-group person-group-type="editor"><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Semana</surname><given-names>G</given-names></name><name><surname>Tiercy</surname><given-names>JM</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Blasczyk</surname><given-names>R</given-names></name><etal/></person-group><source>12th AHS#2 report 1</source><publisher-loc>Sevres</publisher-loc><publisher-name>Medical and Scientific International Publisher</publisher-name><fpage>35</fpage><lpage>41</lpage></citation></ref><ref id="pntd.0000304-Butt1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>N</given-names></name><name><surname>Abbassi</surname><given-names>A</given-names></name><name><surname>Munir</surname><given-names>SM</given-names></name><name><surname>Ahmad</surname><given-names>SM</given-names></name><name><surname>Sheikh</surname><given-names>QH</given-names></name></person-group><year>2008</year><article-title>Haematological and Biochemical Indicators for the Early Diagnosis of Dengue Viral Infection.</article-title><source>J Coll Physicians Surg Pak</source><volume>18</volume><fpage>282</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">18541082</pub-id></citation></ref><ref id="pntd.0000304-Faridi1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faridi</surname><given-names>MM</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Sarafrazul</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>Clinical and biochemical profile of dengue haemorrhagic fever in children in Delhi.</article-title><source>Trop Doct</source><volume>38</volume><fpage>28</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18302860</pub-id></citation></ref><ref id="pntd.0000304-DazQuijano1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D&#x000ed;az-Quijano</surname><given-names>FA</given-names></name><name><surname>Mart&#x000ed;nez-Vega</surname><given-names>RA</given-names></name><name><surname>Villar-Centeno</surname><given-names>LA</given-names></name></person-group><year>2005</year><article-title>Early indicators of severity in dengue virus infection.</article-title><source>Enferm Infecc Microbiol Clin</source><volume>23</volume><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">16324564</pub-id></citation></ref><ref id="pntd.0000304-Pham1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>TB</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Vu</surname><given-names>TQ</given-names></name><name><surname>Nguyen</surname><given-names>TL</given-names></name><name><surname>Malvy</surname><given-names>D</given-names></name></person-group><year>2007</year><article-title>Predictive factors of dengue shock syndrome at the Children hospital No.1, Ho Chi Minh City, Vietnam.</article-title><source>Bull Soc Pathol Exot</source><volume>100</volume><fpage>43</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17402695</pub-id></citation></ref><ref id="pntd.0000304-Chao1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>DY</given-names></name><name><surname>Lin</surname><given-names>TH</given-names></name><name><surname>Hwang</surname><given-names>KP</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>King</surname><given-names>CC</given-names></name></person-group><year>2004</year><article-title>1998 dengue hemorrhagic fever in Taiwan.</article-title><source>Emer Infect Dis</source><volume>10</volume><fpage>552</fpage><lpage>553</lpage></citation></ref><ref id="pntd.0000304-Sriprom1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sriprom</surname><given-names>M</given-names></name><name><surname>Pongsumpun</surname><given-names>P</given-names></name><name><surname>Yoksan</surname><given-names>S</given-names></name><name><surname>Barbazan</surname><given-names>P</given-names></name><name><surname>Gonzaler</surname><given-names>JP</given-names></name><etal/></person-group><year>2003</year><article-title>Dengue hemorrhagic fever in Thailand, 1998-2003: Primary or secondary infection.</article-title><source>Dengue Bull</source><volume>27</volume><fpage>39</fpage><lpage>45</lpage></citation></ref><ref id="pntd.0000304-Halstead2"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name><name><surname>Lan</surname><given-names>NT</given-names></name><name><surname>Myint</surname><given-names>TT</given-names></name><name><surname>Shwe</surname><given-names>TN</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored.</article-title><source>Emerg Infect Dis</source><volume>8</volume><fpage>1474</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">12498666</pub-id></citation></ref><ref id="pntd.0000304-Islam1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>MA</given-names></name><name><surname>Ahmed</surname><given-names>MU</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><name><surname>Chowdhury</surname><given-names>NA</given-names></name><name><surname>Khan</surname><given-names>AH</given-names></name><etal/></person-group><year>2006</year><article-title>Molecular characterization and clinical evaluation of dengue outbreak in 2002 in Bangladesh.</article-title><source>Jpn J Infect Dis</source><volume>59</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16632907</pub-id></citation></ref><ref id="pntd.0000304-Vaughn1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Kalayanarooj</surname><given-names>S</given-names></name><name><surname>Innis</surname><given-names>BL</given-names></name><name><surname>Nimmannitya</surname><given-names>S</given-names></name><etal/></person-group><year>2000</year><article-title>Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.</article-title><source>J Infect Dis</source><volume>181</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10608744</pub-id></citation></ref><ref id="pntd.0000304-ParadoaPerez1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paradoa Perez</surname><given-names>ML</given-names></name><name><surname>Trujillo</surname><given-names>Y</given-names></name><name><surname>Basanta</surname><given-names>P</given-names></name></person-group><year>1987</year><article-title>Association of dengue hemorrhagic fever with the HLA system.</article-title><source>Haematol</source><volume>20</volume><fpage>83</fpage><lpage>87</lpage></citation></ref><ref id="pntd.0000304-BeatrizSierra1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beatriz Sierra</surname></name><name><surname>Roberto Alegre</surname></name><name><surname>P&#x000e9;rez</surname><given-names>AnaB</given-names></name><name><surname>Gissel Garc&#x000ed;a</surname></name><etal/></person-group><year>2007</year><article-title>HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: Advantages of the Cuban population for HLA studies of dengue virus infection.</article-title><source>Human Immunol</source><volume>68</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">17509453</pub-id></citation></ref><ref id="pntd.0000304-Sidney1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Frahm</surname><given-names>N</given-names></name><name><surname>Brander</surname><given-names>C</given-names></name><name><surname>Settle</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>HLA class I supertypes: a revised and updated classification.</article-title><source>BMC Immunol</source><volume>9</volume><fpage>1 doi: 10.1186/1471-2172-9-1</fpage><pub-id pub-id-type="pmid">18211710</pub-id></citation></ref><ref id="pntd.0000304-Umapathy1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umapathy</surname><given-names>S</given-names></name><name><surname>Pawar</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>K</given-names></name></person-group><year>2007</year><article-title>Specific human leukocyte antigen alleles associated with HIV-1 infection in an Indian population.</article-title><source>J Acquir Immune Defic Syndr</source><volume>44</volume><fpage>489</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">17353719</pub-id></citation></ref><ref id="pntd.0000304-Mathew1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>A</given-names></name><name><surname>Kurane</surname><given-names>I</given-names></name><name><surname>Rothman</surname><given-names>AL</given-names></name><name><surname>Zeng</surname><given-names>LL</given-names></name><name><surname>Brinton</surname><given-names>MA</given-names></name><etal/></person-group><year>1996</year><article-title>Dominant recognition by human CD8-cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a.</article-title><source>J Clin Invest</source><volume>98</volume><fpage>1684</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">8833919</pub-id></citation></ref><ref id="pntd.0000304-Simmons1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>Cp</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Chau</surname><given-names>NV</given-names></name><name><surname>Dung</surname><given-names>NT</given-names></name><name><surname>Chau</surname><given-names>TN</given-names></name><etal/></person-group><year>2005</year><article-title>Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.</article-title><source>J Virol</source><volume>79</volume><fpage>5665</fpage><lpage>5675</lpage><pub-id pub-id-type="pmid">15827181</pub-id></citation></ref><ref id="pntd.0000304-Maureen1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maureen</surname><given-names>PM</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Immunogenetics of viral infections.</article-title><source>Curr Opin Immunol</source><volume>17</volume><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">16084708</pub-id></citation></ref><ref id="pntd.0000304-LaFleur1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LaFleur</surname><given-names>C</given-names></name><name><surname>Granados</surname><given-names>J</given-names></name><name><surname>Vargas-Alarcon</surname><given-names>G</given-names></name><name><surname>Ruiz-Morales</surname><given-names>J</given-names></name><name><surname>Villarreal-Garza</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever.</article-title><source>Hum Immunol</source><volume>63</volume><fpage>1039</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">12392857</pub-id></citation></ref><ref id="pntd.0000304-Charron2"><label>41</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Charron</surname><given-names>D</given-names></name></person-group><year>1997</year><article-title>12th International Histocompatibility Workshop and Conference Proceedings: Genetic Diversity of HLA: Functional and Medical Implications.</article-title><person-group person-group-type="editor"><name><surname>Clayton</surname><given-names>J</given-names></name><name><surname>Lonjou</surname><given-names>C</given-names></name></person-group><source>Whittle D. Allele and haplotype frequencies for HLA loci in various ethnic groups</source><publisher-loc>Sevres</publisher-loc><publisher-name>Medical and Scientific International Publisher</publisher-name><fpage>665</fpage><lpage>775</lpage></citation></ref><ref id="pntd.0000304-Burdett1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burdett</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Tu</surname><given-names>B</given-names></name><name><surname>Guiterrez</surname><given-names>M</given-names></name><name><surname>Buck</surname><given-names>K</given-names></name><name><surname>Maiers</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>DRB-DQB1 diversity in the analysis of 4727 donors tested by SBT.</article-title><source>Human Immunology</source><volume>64</volume><fpage>S6</fpage></citation></ref><ref id="pntd.0000304-Tokushige1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokushige</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>E</given-names></name><name><surname>Yamauchi</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV.</article-title><source>Am J Gastroenterol</source><volume>98</volume><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">12526952</pub-id></citation></ref><ref id="pntd.0000304-Aikawa1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aikawa</surname><given-names>T</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Onishi</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>R</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><etal/></person-group><year>1996</year><article-title>HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatic C.</article-title><source>J Med Virol</source><volume>49</volume><fpage>274</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">8877758</pub-id></citation></ref><ref id="pntd.0000304-Chaturvedi3"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>UC</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Elbishbish</surname><given-names>EA</given-names></name><name><surname>Mustafa</surname><given-names>AS</given-names></name></person-group><year>2000</year><article-title>Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis.</article-title><source>FEMS Immunol Med Mic</source><volume>28</volume><fpage>183</fpage><lpage>188</lpage></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p>This work was supported in part by grants in aid from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT) for the 21c COE program, for funding the overseas laboratory for the research network for infectious diseases and for the Tokutei research 2003&#x02013;2005. N.T.P.L was given the Monbusho scholarship from MEXT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 